60 Degrees Pharmaceuticals Updates on Conference Presentation
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) is a pioneering pharmaceutical company dedicated to advancing healthcare solutions for vector-borne diseases. The company recently announced an important update regarding its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The live presentation featuring CEO Dr. Geoff Dow is now scheduled for Tuesday, September 9, at 3:30 PM Eastern Time.
Live Presentation Details
The conference, hosted in New York City, will see Dr. Dow discuss the company's innovative approaches and future plans for their treatments. This is a prime opportunity for investors and stakeholders to gain insights directly from the management team of 60 Degrees Pharmaceuticals. There will also be an opportunity for one-on-one meetings, allowing interested parties to engage directly and ask specific questions.
Conference Agenda
This year's event has attracted attention and interest due to its focus on critical developments in biotechnology and pharmaceuticals. 60 Degrees Pharmaceuticals aims to capture this attention through a detailed presentation that highlights its latest research, product pipelines, and partnerships. The conference will be held at the prestigious Lotte New York Palace Hotel, further establishing the company’s commitment to high-profile engagement with investors.
Innovations in Vector-Borne Disease Treatment
Founded in 2010, 60 Degrees Pharmaceuticals has distinguished itself as a frontrunner in developing and commercializing medications crucial for the treatment and prevention of vector-borne diseases. The company made headlines in 2018 by receiving FDA approval for its flagship product, ARAKODA (tafenoquine), specifically designed for malaria prevention. ARAKODA is currently available in both the U.S. and Australia, demonstrating the company’s international presence and commitment to combatting significant health challenges.
Company Collaborations
Collaboration is a hallmark of 60 Degrees Pharmaceuticals’ strategy. The company partners with eminent research and academic institutions across both the United States and Australia to enhance its research capabilities and innovate more effective healthcare solutions. These collaborations are vital for maintaining a competitive edge in the rapidly evolving pharmaceutical landscape.
Future Prospects
As 60 Degrees Pharmaceuticals prepares for the conference, the upcoming presentation is expected to highlight not just past successes, but also future directions. This is an exciting time for the company as it remains dedicated to its mission of developing new medicines aimed at saving lives and improving the quality of health for people affected by vector-borne diseases.
Contact Information
For those interested in learning more about 60 Degrees Pharmaceuticals, the company encourages stakeholders and media representatives to reach out. Media inquiries can be directed to Sheila A. Burke at (484) 667-6330 or via email at SheilaBurke-consultant@60degreespharma.com. Investor relations can be directed to Patrick Gaynes at patrickgaynes@60degreespharma.com.
Frequently Asked Questions
What is the focus of 60 Degrees Pharmaceuticals?
60 Degrees Pharmaceuticals specializes in developing innovative treatments for vector-borne diseases.
When is the live presentation at H.C. Wainwright Conference?
The live presentation is set for September 9 at 3:30 PM Eastern Time.
Where is the conference being held?
The conference will be hosted at the Lotte New York Palace Hotel in New York City.
What product did 60 Degrees Pharmaceuticals gain FDA approval for?
The company gained FDA approval for ARAKODA (tafenoquine), a medication for malaria prevention.
How can I contact 60 Degrees Pharmaceuticals for media inquiries?
You can reach Sheila A. Burke at (484) 667-6330 or via email at SheilaBurke-consultant@60degreespharma.com.
